

Electronic Supplementary Information:

Gallium(III) and Iron(III) Complexes of Quinolone Antimicrobials

Katja Dralle Mjos, Jacqueline F. Cawthray, Elena Polishchuk,

Michael J. Abrams, Chris Orvig*

Medicinal Inorganic Chemistry Group, Department of Chemistry,

University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada

*Email: orvig@chem.ubc.ca

Contents

S1 Characterization of Quinolone Antimicrobial Agents	S3
S1.1 Ciprofloxacin, Hcipro	S3
S1.2 Enoxacin, Henox	S4
S1.3 Fleroxacin, Hflex	S4
S1.4 Levofloxacin, Hlevox	S5
S1.5 Lomefloxacin, Hlomx	S6
S1.6 Nalidixic acid, Hnxa	S7
S1.7 Norfloxacin, Hnofx	S8
S1.8 Oxolinic acid, Hoxa	S9
S1.9 Pipemidic acid, Hpia	S9
S2 Synthesis & Characterization of Tris(quinolono)metal(III) Complexes	S10

S2.1	Tris(ciprofloxacinogallium(III), [Ga(cipro) ₃]	S11
S2.2	Tris(enoxacinogallium(III), [Ga(enox) ₃]	S12
S2.3	Tris(fleroxacinogallium(III), [Ga(flex) ₃]	S13
S2.4	Tris(levofloxacinogallium(III), [Ga(levox) ₃]	S14
S2.5	Tris(lomefloxacinogallium(III), [Ga(lomx) ₃]	S15
S2.6	Tris(nalidixogallium(III), [Ga(nxa) ₃]	S17
S2.7	Tris(norfloxacinogallium(III), [Ga(nofx) ₃]	S18
S2.8	Tris(oxalino)gallium(III), [Ga(oxa) ₃]	S19
S2.9	Tris(pipemido)gallium(III), [Ga(pia) ₃]	S19
S2.10	Tris(ciprofloxacin)iron(III), [Fe(cipro) ₃]	S20
S2.11	Tris(enoxacin)iron(III), [Fe(enox) ₃]	S20
S2.12	Tris(fleroxacin)iron(III), [Fe(flex) ₃]	S21
S2.13	Tris(levofloxacin)iron(III), [Fe(levox) ₃]	S21
S2.14	Tris(lomefloxacin)iron(III), [Fe(lomx) ₃]	S22
S2.15	Tris(nalidix)iron(III), [Fe(nxa) ₃]	S22
S2.16	Tris(norfloxacin)iron(III), [Fe(nofx) ₃]	S23
S2.17	Tris(oxalino)iron(III), [Fe(oxa) ₃]	S23
S2.18	Tris(pipemido)iron(III), [Fe(pia) ₃]	S24
S3 Synthesis & Characterization of Tris(maltolato)metal(III) Complexes		S24
S3.1	Tris(maltolato)gallium(III), [Ga(ma) ₃]	S24
S3.2	Tris(maltolato)iron(III), [Fe(ma) ₃]	S25
S4 Antimicrobial Susceptibility Single-Disk Test Procedure		S25
S5 MIC and IC₅₀ Studies		S27

S1 Characterization of Quinolone Antimicrobial Agents

S1.1 Ciprofloxacin, Hcipro

Appearance: off-white solid. **Mp:** 253–255°C (brown). **UV-Vis** (CH₃OH with 1.5% DMSO): λ [nm] (ϵ) [$M^{-1}cm^{-1}$] = 289 (19900), 317 (12500), 331 (11800). **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3044 (m, br), 2844 (w, br) 1614 (st), 1587 (st), 1540 (md), 1498 (st), 1472 (md), 1448 (sh), 1372 (st, br), 1329 (md), 1310 (w), 1284 (st), 1260 (sh), 1172 (md), 1146 (st), 1130 (sh), 1102 (w), 1076 (w), 1035 (st), 1022 (st), 978 (w), 934 (st), 891 (md), 868 (st), 833 (st), 822 (md), 784 (st), 721 (st), 707 (md), 652 (md), 622 (st), 565 (st), 553 (sh), 543 (st), 494 (st), 479 (sh), 443 (md). **NMR:** δ_H (600 MHz, 298 K, d_6 -DMSO) [ppm] = 14.68 (br s, 1H, COOH); 8.67 (s, 1 H, $C_{ar2}H$); 7.93 (d, $J_{H,F}^3 = 13.0$ Hz, 1 H, $C_{ar5}H$); 7.60 (d, $J_{H,F}^4 = 7.4$ Hz, 1 H, $C_{ar8}H$); 3.86 (tt, $J_{H,H}^3 = 7.2, 3.7$ Hz, 1 H, $C_{prop}H$); 3.54 (t, $J_{H,H}^3 = 5.0$ Hz, 4 H, $C_{pip2,6}H_2$); 3.27 (t, $J_{H,H}^3 = 5.0$ Hz, 4 H, $C_{pip3,5}H_2$); 1.34–1.31 (m, 2 H, $C_{prop}H_{b,b'}$);¹ 1.20–1.17 (m, 2 H, $C_{prop}H_{a,a'}$). δ_C (125 MHz, 298 K, d_6 -DMSO) [ppm] = 176.4 (s, C_{ar4}); 165.9 (s, COOH); 152.9 (d, $J_{C,F}^1 = 207.9$ Hz, C_{ar6}); 148.2 (s, C_{ar2}); 144.3 (d, $J_{C,F}^2 = 7.9$ Hz, C_{ar7}); 139.1 (s, $C_{ar8'}$); 119.2 (d, $J_{C,F}^3 = 5.9$ Hz, $C_{ar4'}$); 111.2 (d, $J_{C,F}^2 = 19.1$ Hz, C_{ar5}); 108 (from HMBC, C_{ar3}); 106.8 (s, C_{ar8}); 46.8 (s, $C_{pip2,6}$); 42.8 (s, $C_{pip3,5}$); 36.0 (s, $C_{prop}H$); 7.6 (s, $C_{prop}H_2$). δ_F (282 MHz, 298 K, d_6 -DMSO) [ppm] = -121.8 (s, 1 F, $C_{ar6}F$). **MS** (ES+, CH₃OH): m/z (%) = 332 (100) [HL + H⁺]. m/z (%) = 685 (100) [(HL)₂ + Na⁺]. **EA:** Anal. Calcd. (found) [%] for C₁₇H₁₈FN₃O₃: C, 61.62 (61.76); H, 5.48 (5.52); N, 12.68 (12.46).

S1.2 Enoxacin, Henox

Appearance: off-white, fine crystalline solid. **Mp:** 226–228°C (yellow). **UV-Vis** (CH₃OH with 1.1% DMSO): λ [nm] (ϵ) [$M^{-1}cm^{-1}$] = 287 (14900), 345 (17800). **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3390 (md, br), 2835 (st, br), 2773 (md, br), 2556 (md, br), 1625 (st), 1577 (st), 1468 (sh), 1440 (st), triple crown motif [1403 (md), 1365 (st), 1340 (st)], 1271 (st, br), 1172 (md), 1144 (md), 1107 (md), 1037 (md, br), 942 (st, br), 918 (sh), 826 (st), 790 (md), 729 (md, br), 681 (md), 639 (w), 622 (st), 546 (w), 561 (w), 524 (w), 474 (md, br). **NMR:** δ_H (300 MHz, 298 K, *d*₆-DMSO) [ppm] = 8.93 (s, 1 H, *C*_{ar2}*H*); 7.98 (d, $J_{H,F}^3 = 13.8$ Hz, 1 H, *C*_{ar5}*H*); 4.45 (q, $J_{H,H}^3 = 7.1$ Hz, 2 H, CH₂CH₃); 3.73 (dd, $J_{H,H}^3 = 5.9, 4.1$ Hz, 4 H, *C*_{pip2,6}*H*₂); 2.84 (dd, $J_{H,H}^3 = 5.9, 4.1$ Hz, 4 H, *C*_{pip3,5}*H*₂); 1.37 (t, $J_{H,H}^3 = 7.1$ Hz, 3 H, CH₂CH₃). δ_C (75 MHz, 298 K, *d*₆-DMSO) [ppm] = 176.2 (d, $J_{C,F}^4 = 2.3$ Hz, *C*_{ar4}); 168.0 (s, *C*_{ar8'}); 165.9 (s, COOH); 149.9 (d, $J_{C,F}^2 = 9.0$ Hz, *C*_{ar7}); 147.5 (s, *C*_{ar2}); 146.2 (d, $J_{C,F}^1 = 204.2$ Hz, *C*_{ar6}); 119.2 (d, $J_{C,F}^2 = 22.0$ Hz, *C*_{ar5}); 112.2 (d, $J_{C,F}^3 = 3.6$ Hz, *C*_{ar4'}); 108.0 (s, *C*_{ar3}); 48.2 (d, $J_{C,F}^4 = 7.9$ Hz, *C*_{pip2,6}); 47.1 (s, CH₂CH₃); 45.6 (s, *C*_{pip3,5}); 14.6 (s, CH₂CH₃). δ_F (282 MHz, 298 K, *d*₆-DMSO) [ppm] = -127.3 (s, 1 F, *C*_{ar6}*F*). **MS** (ES+): *m/z* (%) = 321 (100) [HL + H⁺]. *m/z* (%) = 664 (100) [(HL)₂ + Na⁺]. **EA:** Anal. Calcd. (found) [%] for C₁₅H₁₇FN₄O₃·1.5 H₂O: C, 51.87 (51.60); H, 5.80 (5.67); N, 16.13 (15.86).

S1.3 Fleroxacin, Hflex

Appearance: white solid. **Mp:** 260°C (decomposed, pale yellow). **UV-Vis** (CH₃OH with 1.5% DMSO): λ [nm] (ϵ) [$M^{-1}cm^{-1}$] = 294 (27500), 320 (12400), 330 (11500). **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3054 (md), 2941 (md), 2796 (md), 1716 (st), 1622 (st), 1556 (md), 1542 (sh), 1513 (md), 1474 (st, br), 1447 (st), 1408 (md), 1390 (w), 1375 (md), 1360 (md), 1327 (md), 1279 (st, br), 1244 (md), 1228 (md), 1214 (md), 1205 (md), 1142 (st), 1122 (sh),

1098 (md), 1061 (st), 1036 (st), 1019 (sh), 1010 (st), 970 (st), 941 (st), 925 (st), 869 (md), 852 (md), 816 (sh), 806 (st), 783 (md), 754 (sh), 741 (st), 672 (w), 656 (md, br), 573 (md), 550 (md), 532 (w), 504 (md), 450 (md, br). **NMR:** δ_{H} (600 MHz, 298 K, d_6 -DMSO) [ppm] = 14.77 (br s, 1 H, COOH); 8.84 (s, 1 H, $C_{ar2}H$); 7.86 (d, $J_{H,F}^3 = 11.9$ Hz, 1 H, $C_{ar5}H$); 4.97–4.84 (m, 4 H, $(CH_2)_2$); 3.34 (br s, 4 H, $C_{pip2,6}H_2$, overlaid with water); 2.45 (br s, 4 H, $C_{pip3,5}H_2$); 2.23 (s, 3 H, CH_3). δ_{C} (125 MHz, 298 K, d_6 -DMSO) [ppm] = 175.6 (s, C_{ar4}); 165.5 (s, COOH); 154.5 (d, $J_{C,F}^1 = 208.2$ Hz, C_{ar6}); 152.1 (s, C_{ar2}); 146.0 (d, $J_{C,F}^1 = 212.2$ Hz, C_{ar8}); 133.7 (two overlapping d, $J_{C,F}^2 = 13.9, 11.7$ Hz, C_{ar7}); 127.3 (d, $J_{C,F}^2 = 9.1$ Hz, $C_{ar8'}$); 120.1 (d, $J_{C,F}^3 = 35.1$ Hz, $C_{ar4'}$); 107.0 (d, $J_{C,F}^2 = 19.2$ Hz, C_{ar5}); 106 (from HMBC, C_{ar3}); 82.1 (d, $J_{C,F}^1 = 138.2$ Hz, CH_2CH_2F); 57.8 (two overlapping d, $J_{C,F} = 15.8, 12.2$ Hz, CH_2CH_2F); 55.1 (s, $C_{pip2,6}$); 50.3 (s, $C_{pip3,5}$); 46.0 (s, CH_3). δ_{F} (282 MHz, 298 K, d_6 -DMSO) [ppm] = -119.2 (d, $J_{F,F}^4 = 11.9$ Hz, 1 F, $C_{ar6}F$); -127.6 (q, $J_{F,F} = 5.9$ Hz, 1 F, $C_{ar8}F$); -224.1 (d, $J_{F,F}^6 = 5.9$ Hz, 1 F, $(CH_2)_2F$). **MS** (ES+): m/z (%) = 370 (100) [HL + H⁺], 762 (80) [(HL)₂ + Na⁺]. **EA:** Anal. Calcd. (found) [%] for C₁₇H₁₈F₃N₃O₃: C, 55.28 (55.14); H, 4.91 (4.90); N, 11.38 (10.98).

S1.4 Levofloxacin, Hlevox

Appearance: pale yellow solid. **Mp:** 224–226°C (dark brown). **UV-Vis** (CH₃OH with 1.5% DMSO): λ [nm] (ϵ) [M⁻¹cm⁻¹] = 299 (25100), 318 (10200). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3247 (md, br), 2935 (md), 2884 (md), 2848 (md), 2802 (md), 1720 (st), 1619 (st), 1538 (md), 1518 (md), 1492 (md), 1468 (sh), 1439 (st, br), 1414 (sh), 1394 (st), 1359 (md), 1340 (st), 1315 (sh), 1289 (st), 1240 (st), 1207 (sh), 1195 (md), 1163 (md), 1136 (st), 1116 (md), 1086 (st, br), 1066 (sh), 1048 (md), 1004 (st), 963 (sh), 951 (md, br), 903 (sh), 873 (st), 839 (md), 800 (st), 778 (md), 755 (md), 741 (st), 727 (md), 695 (w), 666 (w), 650 (st), 578

(w), 559 (st), 490 (md), 459 (md). **NMR:** δ_H (600 MHz, 298 K, d_6 -DMSO) [ppm] = 15.20 (br s, 1 H, COOH); 8.96 (s, 1 H, $C_{ar2}H$); 7.56 (d, $J_{H,F}^3 = 12.4$ Hz, 1 H, $C_{ar5}H$); 4.91 (d, $J_{H,H} = 6.8$ Hz, 1 H, CH); 4.58 (dd, $J_{H,H} = 11.5, 1.7$ Hz, 1 H) and 4.36 (dd, $J_{H,H} = 11.5, 2.3$ Hz, 1 H) (OCH₂CH); 3.33–3.25 (m, 4 H, $C_{pip2,6}H_2$); 2.43 (br s, 4 H, $C_{pip3,5}H_2$); 2.23 (s, 3 H, NCH₃); 1.44 (d, $J_{H,H}^3 = 3.3$ Hz, 3 H, CHCH₃). δ_C (125 MHz, 298 K, d_6 -DMSO) [ppm] = 176.4 (s, C_{ar4}); 166.1 (s, COOH); 155.5 (d, $J_{C,F}^1 = 206.3$ Hz, C_{ar6}); 146.2 (s, C_{ar2}); 140.1 (d, $J_{C,F}^3 = 5.7$ Hz, C_{ar8}); 132.1 (d, $J_{C,F}^2 = 11.9$ Hz, C_{ar7}); 124.8 (s, $C_{ar8'}$); 119.6 (d, $J_{C,F}^3 = 7.7$ Hz, $C_{ar4'}$); 106.6 (s, C_{ar3}); 103.3 (d, $J_{C,F}^2 = 20.4$ Hz, C_{ar5}); 68.0 (s, OCH₂CH); 55.3 (s, $C_{pip2,6}$); 54.8 (s, CH); 50.1 (s, $C_{pip3,5}$); 46.1 (s, NCH₃); 17.9 (s, CH(CH₃)). δ_F (282 MHz, 298 K, d_6 -DMSO) [ppm] = -120.2 (s, 1 F, $C_{ar6}F$). **MS** (ES+): m/z (%) = 362 (100) [HL + H⁺]. m/z (%) = 541 (100), 745 (60) [(HL)₂ + Na⁺], 1173 (30). **EA:** Anal. Calcd. (found) [%] for C₁₈H₂₀FN₃O₄: C, 59.83 (59.44); H, 5.58 (5.66); N, 11.63 (11.43).

S1.5 Lomefloxacin, Hlomx

Appearance: white solid. **Mp:** >260°C. **UV-Vis** (CH₃OH with 1.1% DMSO): λ [nm] (ϵ) [M⁻¹cm⁻¹] = 291 (34500), 320 (15800), 332 (13100). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3055 (w), 2936 (md), 2842 (w), 2756 (sh), 2698 (st, br), 2456 (md), 1721 (st), 1611 (st), 1543 (sh), 1524 (md), 1491 (st), 1471 (sh), 1448 (st, br), 1411 (w), 1392 (st), 1328 (st), 1299 (md), 1281 (md), 1253 (st), 1205 (st), 1182 (w), 1166 (w), 1141 (md), 1114 (md), 1093 (st), 1065 (w), 1041 (st), 1021 (md), 1006 (st), 979 (md), 928 (st), 892 (st), 844 (md), 821 (md), 807 (st), 791 (sh), 756 (sh), 738 (st), 653 (md), 578 (w), 555 (md), 545 (md), 534 (md), 513 (st), 488 (md), 476 (md), 452 (md). **NMR:** δ_H (600 MHz, 298 K, D₂O) [ppm] = 8.55 (s, 1 H, $C_{ar2}H$); 7.46 (d, $J_{H,F}^3 = 11.4$ Hz, 1 H, $C_{ar5}H$); 4.48 (d, $J_{H,H}^3 = 6.0$ Hz, 2H, CH₂CH₃); 3.70–3.53 (m, 5 H, $C_{pip2,6}H_2$ and $C_{pip3}H$); 3.42–3.38 (m, 2 H, $C_{pip4}H_2$); 1.49

(t, $J_{H,H}^3 = 7.1$ Hz, 3 H, CH_2CH_3); 1.40 (d, $J_{H,H}^3 = 6.6$ Hz, 3 H, CH_3). δ_{C} (125 MHz, 298 K, d_6 -DMSO) [ppm] = 175.3 (s, C_{ar4}); 168.3 (COOH); 154.9 (d, $J_{C,F}^1 = 208.6$ Hz, C_{ar6}); 150.6 (s, C_{ar2}); 146.1 (d, $J_{C,F}^1 = 210.3$ Hz, C_{ar8}); 133.0 (two overlapping d, $J_{C,F}^2 = 11.6, 11.6$ Hz, C_{ar7}); 127.0 (d, $J_{C,F}^2 = 5.6$ Hz, $C_{ar8'}$); 120.8 (d, $J_{C,F}^3 = 7.3$ Hz, $C_{ar4'}$); 106.8 (d, $J_{C,F}^2 = 19.1$ Hz, C_{ar5}); 106.1 (s, C_{ar3}); 55.0 (d, $J_{C,F}^4 = 13.5$ Hz, C_{pip2}); 53.4 (s, CH_2CH_3); 51.7 (s, C_{pip6}); 46.7 (s, C_{pip3}); 43.5 (s, C_{pip5}); 15.3 (s, CH_2CH_3); 14.9 (s, CH_3). δ_{F} (282 MHz, 298 K, d_6 -DMSO) [ppm] = -118.6 (d, $J_{F,F}^4 = 10.7$ Hz, 1 F, C_{ar6F}); -128.6 (d, $J_{F,F}^4 = 11.3$ Hz, 1 F, C_{ar8F}). **MS** (ES+): m/z (%) = 352 (100) [HL + H^+]. m/z (%) = 769 (100), 725 (60) [(HL) $_2$ + Na^+], 1143 (30). **EA**: Anal. Calcd. (found) [%] for $\text{C}_{17}\text{H}_{20}\text{F}_2\text{N}_3\text{O}_3 \cdot 1 \text{HCl}$: C, 52.65 (52.79); H, 5.20 (5.17); N, 10.84 (10.56).

S1.6 Nalidixic acid, Hnxa

Appearance: white solid. **Mp**: 228–230°C (soft pink). **UV-Vis** (CH_3OH with 1.1% DMSO): λ [nm] (ϵ) [$\text{M}^{-1}\text{cm}^{-1}$] = 320 (13500), 328 (13700). **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3044 (md, br), 2987 (w, br), 2948 (w), 1707 (st, br), 1614 (st, br), 1562 (w), 1538 (w), 1518 (md), 1465 (sh), 1440 (st, br), 1384 (w), 1370 (md), 1353 (md), 1327 (w), 1294 (md), 1270 (sh), 1252 (st), 1227 (st), 1129 (st), 1102 (w), 1051 (w), 1034 (w), 971 (st, br), 875 (md), 803 (st), 777 (sh), 706 (md), 656 (md), 634 (md), 563 (w), 539 (md), 505 (w), 485 (st), 454 (md). **NMR**: δ_{H} (300 MHz, 298 K, d_6 -DMSO) [ppm] = 9.18 (s, 1 H, C_{ar2H}); 8.60 (d, $J_{H,H}^3 = 8.2$ Hz, 1 H, C_{ar5H}); 7.59 (d, $J_{H,H}^3 = 8.2$ Hz, 1 H, C_{ar6H}); 4.64 (q, $J_{H,H}^3 = 7.1$ Hz, 2 H, CH_2CH_3); 2.71 (s, 3 H, CH_3); 1.42 (t, $J_{H,H}^3 = 7.1$ Hz, 3 H, CH_2CH_3). δ_{C} (75 MHz, 298 K, d_6 -DMSO) [ppm] = 178.2 (s, C_{ar4}); 165.6 (s, $C_{ar8'}$); 164.7 (s, COOH); 149.7 (s, C_{ar2}); 148.3 (s, C_{ar7}); 135.6 (s, C_{ar5}); 122.6 (s, C_{ar6}); 118.3 (s, $C_{ar4'}$); 108.6 (s, C_{ar3}); 46.8 (s, CH_2CH_3); 25.1 (s, CH_3); 15.0 (s, CH_2CH_3). **MS** (ES+): m/z (%) = 255 (100)

[HL + Na⁺], 233 (60) [HL + H⁺]. m/z (%) = 786 (100) [(HL)₃ + Na⁺], 1040 (30) [(HL)₄ + Na⁺], 1294 (10) [(HL)₅ + Na⁺]. **EA**: Anal. Calcd. (found) [%] for C₁₂H₁₂N₂O₃: C, 62.06 (62.32); H, 5.21 (5.18); N, 12.06 (11.94).

S1.7 Norfloxacin, Hnofx

Appearance: pale yellow solid. **Mp**: 221–223°C (yellow). **UV-Vis** (CH₃OH with 1.5% DMSO): λ [nm] (ϵ) [M⁻¹cm⁻¹] = 290 (21900), 317 (9900), 330 (8700). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3046 (w, br), 2944 (md), 2827 (md, br), 1722 (st), 1614 (st), 1519 (md), 1471 (st), 1439 (st), 1401 (w), 1373 (md), 1350 (md), 1323 (w), 1300 (md), 1272 (w), 1248 (st), 1210 (md), 1198 (st), 1148 (md), 1127 (md), 1102 (st), 1090 (sh), 1050 (w), 1025 (md), 978 (w), 945 (st, br), 885 (st), 838 (st), 826 (sh), 804 (st), 783 (md), 748 (st), 712 (w), 698 (st), 664 (md), 638 (md), 620 (md), 557 (md), 514 (md), 498 (md), 485 (w), 450 (md). **NMR**: δ_{H} (300 MHz, 298 K, *d*₆-DMSO) [ppm] = 8.92 (s, 1 H, C_{ar2}H); 7.85 (d, $J_{\text{H,F}}^3 = 13.5$ Hz, 1 H, C_{ar5}H); 7.12 (d, $J_{\text{H,F}}^4 = 7.3$ Hz, 1 H, C_{ar8}H); 4.57 (q, $J_{\text{H,H}}^3 = 7.1$ Hz, 2 H, CH₂CH₃); 3.22 (dd, $J_{\text{H,H}}^3 = 5.9, 3.8$ Hz, 4 H, C_{pip2,6}H₂); 2.89 (dd, $J_{\text{H,H}}^3 = 5.9, 3.8$ Hz, 4 H, C_{pip3,5}H₂); 1.41 (t, $J_{\text{H,H}}^3 = 7.1$ Hz, 3 H, CH₂CH₃). δ_{C} (75 MHz, 298 K, *d*₆-DMSO) [ppm] = 176.1 (d, $J_{\text{C,F}}^4 = 2.7$ Hz, C_{ar4}); 166.1 (s, COOH); 152.5 (d, $J_{\text{C,F}}^1 = 207.5$ Hz, C_{ar6}); 148.3 (s, C_{ar2}); 145.9 (d, $J_{\text{C,F}}^2 = 9.7$ Hz, C_{ar7}); 137.2 (s, C_{ar8'}); 118.9 (d, $J_{\text{C,F}}^3 = 7.7$ Hz, C_{ar4'}); 111.0 (d, $J_{\text{C,F}}^2 = 23.1$ Hz, C_{ar5}); 107.0 (s, C_{ar3}); 105.4 (d, $J_{\text{C,F}}^3 = 3.7$ Hz, C_{ar8}); 50.8 (d, $J_{\text{C,F}}^4 = 4.8$ Hz, C_{pip2,6}); 49.0 (s, CH₂CH₃); 45.4 (s, C_{pip3,5}); 14.3 (s, CH₂CH₃). δ_{F} (282 MHz, 298 K, *d*₆-DMSO) [ppm] = -121.3 (s, 1 F, C_{ar6}F). **MS** (ES⁺): m/z (%) = 320 (100) [HL + H⁺]. m/z (%) = 662 (70) [2 HL + Na⁺]. **EA**: Anal. Calcd. (found) [%] for C₁₆H₁₈FN₃O₃: C, 60.18 (60.02); H, 5.68 (5.75); N, 13.16 (12.92).

S1.8 Oxolinic acid, Hoxa

Appearance: white solid. **Mp:** >260°C. **UV-Vis** (CH₃OH with 2.2% DMSO): λ [nm] (ϵ) [M⁻¹cm⁻¹] = 322 (7600), 336 (7700). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3061 (md), 2984 (md), 2930 (md, br), 1698 (st), 1632 (st), 1573 (st), 1504 (md), 1440 (st, br), 1384 (md), 1350 (sh), 1301 (md) 1259 (st), 1222 (w), 1204 (w), 1186 (md), 1127 (md), 1094 (w), 1075 (md), 1036 (st), 936 (st, br), 876 (st), 856 (st), 807 (st), 773 (md), 754 (md), 690 (md), 645 (st), 605 (md), 556 (md), 498 (md), 447 (md). **NMR:** δ_H (300 MHz, 298 K, *d*₆-DMSO) [ppm] = 8.89 (s, 1 H, C_{ar2}H); 7.63 (s, 1 H, C_{ar8}H); 7.61 (s, 1 H, C_{ar5}H); 6.29 (s, 2 H, OCH₂O); 4.53 (q, $J_{H,H}^3 = 7.1$ Hz, 2 H, CH₂CH₃); 1.38 (t, $J_{H,H}^3 = 7.1$ Hz, 3 H, CH₂CH₃). δ_C (75 MHz, 298 K, *d*₆-DMSO) [ppm] = 176.0 (s, C_{ar4}); 166.3 (s, COOH); 153.7 (s, C_{ar7}); 147.10 (s, C_{ar6}); 147.0 (s, C_{ar2}); 136.9 (s, C_{ar8'}); 121.3 (s, C_{ar4'}); 107.3 (s, C_{ar3}); 103.3 (s, OCH₂O); 101.8 (s, C_{ar5}); 97.2 (s, C_{ar8}); 49.6 (s, CH₂CH₃); 14.6 (s, CH₂CH₃). **MS** (ES+): m/z (%) = 284 (100) [HL + Na⁺], 262 (10) [HL + H⁺]. m/z (%) = 589 (90) [(HL)₂ + Na⁺], 873 (100) [(HL)₃ + Na⁺], 1156 (30) [(HL)₄ + Na⁺]. **EA:** Anal. Calcd. (found) [%] for C₁₃H₁₁NO₅: C, 59.77 (59.83); H, 4.24 (4.24); N, 5.36 (5.37).

S1.9 Pipemidic acid, Hpia

Appearance: white, fine powdered solid. **Mp:** 258–260°C (orange-brown). **UV-Vis** (CH₃OH with 2.2% DMSO): λ [nm] (ϵ) [M⁻¹cm⁻¹] = 288 (13500), 325 (7300), 342 (5400). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3365 (md, br), 3028 (w), 2979 (w), 1615 (st), 1577 (st), 1532 (md), 1510 (md), 1471 (st), 1429 (st), 1378 (sh), 1357 (st, br), 1309 (md), 1279 (md), 1238 (st, br), 1259 (w), 1159 (w), 1147 (w), 1127 (st), 1092 (md), 1078 (md), 1044 (md) 1022 (st), 975 (md), 940 (md), 914 (st), 903 (md), 867 (md), 832 (st), 802 (md), 783 (md), 743 (st), 715 (md), 655 (w), 608 (w), 540 (st), 489 (md), 453 (md). **NMR:** δ_H (300 MHz, 298 K,

d_6 -DMSO) [ppm] = 9.15 (s, 1 H, $C_{ar5}H$); 8.93 (s, 1 H, $C_{ar2}H$); 4.36 (q, $J_{H,H}^3 = 7.1$ Hz, 2 H, CH_2CH_3); 3.84 (d, $J_{H,H}^3 = 17.1$ Hz, 4 H, $C_{pip2,6}H_2$); 2.78 (br s, 4 H, $C_{pip3,5}H_2$); 1.35 (t, $J_{H,H}^3 = 7.1$ Hz, 3 H, CH_2CH_3). δ_C (75 MHz, 298 K, d_6 -DMSO) [ppm] = 177.1 (s, C_{ar4}); 165.3 (s, $COOH$); 160.5 (C_{ar7}); 160.1 (s, C_{ar5}); 155.1 (s, $C_{ar8'}$); 150.6 (s, C_{ar2}); 109.5 (s, $C_{ar4'}$); 108.3 (s, C_{ar3}); 45.8 (s, CH_2CH_3); 45.3 (br s, $C_{pip2,3,5,6}$); 14.4 (s, CH_2CH_3). **MS** (ES+): m/z (%) = 304 (50) [HL + H^+], 326 (70) [HL + Na^+], 348 (100) [HL + CO_2 + H^+]. m/z (%) = 673 (40) [(NaL) $_2$ + Na^+], 999 (95) [(NaL) $_3$ + Na^+]. **EA**: Anal. Calcd. (found) [%] for $C_{14}H_{17}N_5O_3$: C, 55.44 (55.10); H, 5.65 (5.63); N, 23.09 (22.96).

S2 Synthesis & Characterization of Tris(quinolono)metal(III) Complexes

The tris(quinolino)metal(III) complexes were synthesized according to the following three general synthetic methods:

Method (a): To a solution of metal(III)nitrate nonahydrate (0.1 mmol) in water (2 mL), an acidified aqueous solution (8 mL) of the quinolone (0.3 mmol) was added dropwise. During the addition the pH was carefully monitored and kept below pH 5; finally, raising the pH to pH 7.5 with aqueous sodium hydroxide (1.0 M and 0.1 M) resulted in a characteristically colored solution (yellow for Ga^{3+} , red-brown for Fe^{3+}) that was stirred vigorously at room temperature for 20 min, before the vial was closed tightly and placed in the fridge at 4°C. After 3–5 days the desired product had precipitated. The solid was separated by filtration (glass frit size F), thoroughly washed with water (2 mL) and methanol (2 mL), and dried *in vacuo*.

Method (b) is a modification of the reported synthesis of tris(nalidixido)iron(III):² The

quinolone (0.3 mmol) was heated with sodium bicarbonate or sodium hydroxide (0.3 mmol) in water (10 mL) until the initially white suspension had turned into a clear solution, which was then added onto the solid metal(III) nitrate nonahydrate (0.1 mmol). Upon addition the pH was kept at $\text{pH} \leq 5$, the desired product started forming immediately and precipitated as solid (final $\text{pH} \sim 7$). The suspension was stirred vigorously until it had cooled to room temperature (for a minimum of 30 min, often overnight). The desired product, which precipitated often at room temperature or otherwise after placing the reaction vial in the fridge (4°C) was separated by filtration (glass grit, size F) as a solid, washed with water (2 mL) and methanol (2 mL), and dried *in vacuo*.

Method (c) is a modification of the reported synthesis of tris(ciprofloxacin)iron(III):³ A suspension of quinolone (0.31 mmol) with sodium hydroxide or potassium hydroxide (0.33 mmol) in methanol (15 mL) was refluxed until it turned into a clear, colorless solution. The hot methanolic solution was added onto the solid metal(III)nitrate nonahydrate (0.1 mmol), and the resulting colored solution was refluxed further for thirty minutes. The reaction solution was left to cool in air. Evaporation of the solvent in air, or a reduction of the solvent by at least 50% volume, led to precipitation of a colored solid, which was separated by filtration (glass frit, size F), thoroughly washed with water (2 mL) and methanol (2 mL), and dried *in vacuo*.

The method that gave the highest product purity, as determined by EA and HR-ESI mass spectrometry, at a 0.1 mmol scale is reported.

S2.1 Tris(ciprofloxacin)gallium(III), [Ga(cipro)₃]

Method (c) gave a pale yellow solid (99 mg, 0.094 mmol, 94%). **Mp**: $\geq 220^\circ\text{C}$, decomposition to brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3418 (md, br, water), 2846 (w, br) 1620 (st),

1545 (w), 1516 (sh), 1472 (st), 1451 (sh), 1373 (st, br), 1287 (sh), 1252 (st), 1182 (md) 1146 (md), 1106 (sh), 1025 (st), 949 (st), 893 (md), 810 (md), 787 (md), 765 (sh), 740 (st, br), 704 (md), 627 (st), 540 (md), 505 (st). **NMR:** $\delta_{\mathbf{H}}$ (600 MHz, 298 K, d_6 -DMSO) [ppm] = 8.93 (s), 8.84 (s), 8.80 (s), (3 H, $C_{ar2}H$); 7.65 (d, $J_{H,F}^3 = 13.8$ Hz), 7.57–7.53 (m), 7.41 (d, $J_{H,F}^4 = 7.2$ Hz), (6 H, $C_{ar5}H$ and $C_{ar8}H$); 3.95–3.81 (m, 3 H, $C_{prop}H$); 3.29–3.20 (m, 12 H overlaid with water, $C_{pip2,6}H_2$); 2.96–2.91 (m, 12 H, $C_{pip3,5}H_2$); 1.36–1.32 (m, 6 H, $C_{prop}H_{b,b'}$); 1.23–0.82 (m, 6 H, $C_{prop}H_{a,a'}$). $\delta_{\mathbf{C}}$ (125 MHz, 298 K, d_6 -DMSO) [ppm] = 173.7 (s), 173.6 (s), 173.2 (s), (C_{ar4}); 165.6 (s), 165.5 (s), 165.3 (s), ($COOH$); 153.1 (d, $J_{C,F}^1 = 206.1$ Hz), 153.0 (d, $J_{C,F}^1 = 207.1$ Hz), 152.9 (d, $J_{C,F}^1 = 207.3$ Hz), (C_{ar6}); 149.8 (s), 149.6 (s), 149.3 (s), 149.2 (s), (C_{ar2}); 145.4 (d, $J_{C,F}^2 = 21.0$ Hz), 145.3 (d, $J_{C,F}^2 = 21.8$ Hz), 145.2 (d, $J_{C,F}^2 = 19.5$ Hz), (C_{ar7}); 139.0 (s), 138.8 (s), 138.7 (s), ($C_{ar8'}$); 118.7 (d, $J_{C,F}^3 = 6.9$ Hz), 118.6 (d, $J_{C,F}^3 = 7.0$ Hz), 118.4 (d, $J_{C,F}^3 = 7.8$ Hz), ($C_{ar4'}$); 111.8 (s), 111.7 (s), 111.5 (s), (C_{ar5}); 110.5 (s), 110.3 (s), 110.2 (s), (C_{ar3}); 106.3 (s), 105.7 (s), 105.3 (s), (C_{ar8}); 50.1 (s), 50.0 (s), 49.9 (s), ($C_{pip2,6}$); 45.0 (s), 44.9 (s), 44.8 (s), ($C_{pip3,5}$); 36.2 (s), 36.0 (s), 35.9 (s), 35.8 (s), ($C_{prop}H$); 7.7 (s), 7.6 (s), 7.5 (s), ($C_{prop}H_2$). $\delta_{\mathbf{F}}$ (282 MHz, 298 K, d_6 -DMSO) [ppm] = -121.1 (s), -121.15 (s), -121.21 (s), (3 F, $C_{ar6}F$). **MS** (ES+, CH₃OH): m/z (%) = 1083 (40) [ML₃ + Na⁺], 730 (100) [ML₂]⁺. **HR-ESI-MS:** m/z for C₅₁H₅₁F₃⁶⁹GaN₉O₉ + H⁺ calcd. (found): 1060.3096 (1060.3073); for C₃₄H₃₄F₂⁶⁹GaN₆O₆⁺ calcd. (found): 729.1764 (729.1785). **EA:** Anal. Calcd. (found) [%] for C₅₁H₅₁F₃GaN₉O₉·8 H₂O: C, 50.84 (50.61); H, 5.60 (4.80); N, 10.46 (10.79).

S2.2 Tris(enoxacino)gallium(III), [Ga(enox)₃]

Method (b) gave a pale yellow solid (85 mg, 0.082 mmol, 82%). **Mp:** $\geq 200^\circ\text{C}$, decomposition to light brown solid. **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3404 (md, br, water), 3045 (w, br), 2977

(w, br), 1625 (st), 1562 (md), 1519 (md), 1469 (sh), 1434 (st, br), 1369 (md), 1346 (st), 1323 (md), 1276 (st), 1253 (st, br), 1185 (md), 1153 (w), 1119 (md), 1092 (md), 1039 (md, br), 972 (md), 941 (md, br), 908 (sh), 812 (st), 789 (md), 766 (md), 746 (md), 677 (w), 651 (md), 626 (st), 563 (md), 516 (st), 453 (w). **NMR:** δ_{H} (300 MHz, 298 K, d_6 -DMSO) [ppm] = 9.18 (s), 9.13 (s), 9.08 (s), 9.04 (s), 8.99 (s) (3 H, $C_{ar2}H$); 8.12 (d, $J_{H,F}^3 = 13.2$ Hz), 7.75 (d, $J_{H,F}^3 = 13.2$ Hz), 7.72 (d, $J_{H,F}^3 = 14.0$ Hz), 7.69 (d, $J_{H,F}^3 = 13.8$ Hz), (3 H, $C_{ar5}H$); 4.59–4.43 (m, 6 H, CH_2CH_3); 3.92–3.85 (m, 12 H, $C_{pip2,6}H_2$); 3.12–3.02 (m, 12 H, $C_{pip3,5}H_2$); 1.43–1.23 (m, 9 H, CH_2CH_3). δ_{C} (75 MHz, 298 K, d_6 -DMSO) [ppm] = 173.9 (s), 173.5 (s), 173.4 (s), (C_{ar4}); 168.9 (s), 168.8 (s), 168.7 (s), ($C_{ar8'}$); 165.8 (s), 165.6 (s), 165.5 (s), 165.3 (s), ($COOH$); 149.6 (d, $J_{H,F}^2 = 90.3$ Hz), 149.4 (d, $J_{H,F}^2 = 85.1$ Hz), 149.0 (d, $J_{H,F}^2 = 89.4$ Hz), (C_{ar7}); 147.2 (d, $J_{H,F}^1 = 207.0$ Hz), 147.1 (d, $J_{H,F}^1 = 202.8$ Hz), 147.0 (d, $J_{H,F}^2 = 214.6$ Hz), 146.9 (d, $J_{H,F}^1 = 215.4$ Hz), (C_{ar6}); 144.7 (s), 144.3 (s), 144.1 (s), (C_{ar2}); 119.6 (d, $J_{C,F}^2 = 18.1$ Hz), 119.0 (d, $J_{C,F}^2 = 17.5$ Hz), 118.70 (d, $J_{C,F}^2 = 19.6$ Hz), (C_{ar5}); 113.2–112.6 (m, $C_{ar4'}$); 108.1 (s), 108.0 (s), 109.9 (s), (C_{ar3}); 47.5 (s), 47.3 (s), 47.2 (s), ($C_{pip2,6}$); 46.2 (s), 45.9 (s), 45.6 (s), (CH_2CH_3); 44.2 (s), 44.0 (s), 43.7 (s), ($C_{pip3,5}$); 14.9 (s), 14.8 (s), 14.7 (s), (CH_2CH_3). δ_{F} (282 MHz, 298 K, d_6 -DMSO) [ppm] = -126.4, -126.5, -126.6, -126.8 (3 F, $C_{ar6}F$). **MS** (ES+, CH_3OH): m/z (%) = 1050 (20) [$ML_3 + Na^+$], 708 (100) [ML_2] $^+$. **HR-ESI-MS:** m/z for $C_{45}H_{48}F_3$ $^{69}GaN_{12}O_9 + Na^+$ calcd. (found): 1049.2773 (1049.2797).

S2.3 Tris(fleroxacino)gallium(III), [Ga(flex)₃]

Method (b) gave a pale yellow solid (85 mg, 0.082 mmol, 82%). **Mp:** $\geq 230^\circ\text{C}$, decomposition to orange-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3392 (w, br, water), 3054 (md), 2943 (md), 2848 (w), 2796 (md), 1622 (st), 1556 (md), 1514 (md), 1475 (st, br), 1449 (sh), 1409

(w), 1391 (w), 1376 (md), 1360 (md), 1328 (md), 1280 (st), 1245 (md), 1230 (w), 1214 (w), 1206 (w), 1143 (st), 1123 (md), 1099 (w), 1077 (w), 1062 (md), 1037 (md), 1020 (st), 1010 (st), 970 (md), 942 (md), 926 (md), 869 (md), 853 (md), 807 (st), 783 (md), 754 (sh), 741 (st), 672 (w), 656 (st), 573 (st), 550 (md), 532 (w), 505 (w, br), 450 (md, br). **NMR:** δ_H (600 MHz, 298 K, d_6 -DMSO) [ppm] = 8.86 (s, 3 H, $C_{ar2}H$); 7.87 (d, $J_{H,F}^3 = 11.4$ Hz, 3 H, $C_{ar5}H$); 4.98–4.96 (m), 4.93–4.90 (m), 4.86–4.84 (m) (12 H, $(CH_2)_2$); 3.36 (br s, 12 H overlaid with water, $C_{pip2,6}H_2$); 2.44 (s, 12 H, $C_{pip3,5}H_2$); 2.23 (s, 9 H, CH_3). δ_C (125 MHz, 298 K, d_6 -DMSO) [ppm] = 175.8 (s, C_{ar4}); 165.5 (s, $COOH$); 154.6 (d, $J_{C,F}^1 = 205.9$ Hz), 154.5 (d, $J_{C,F}^1 = 206.5$ Hz), (C_{ar6}); 152.1 (s, C_{ar2}); 146.1 (d, $J_{C,F}^1 = 205.9$ Hz, C_{ar8}), 146.0 (d, $J_{C,F}^1 = 205.9$ Hz, (C_{ar8}); 133.9 (two overlapping d, $J_{C,F}^2 = 11.3, 11.5$ Hz, C_{ar7}); 127.4 (d, $J_{C,F}^2 = 9.1$ Hz, $C_{ar8'}$); 120.1 (d, $J_{C,F}^3 = 6.8$ Hz, $C_{ar4'}$); 107.1 (d, $J_{C,F}^2 = 18.9$ Hz, C_{ar5}); 106.6 (s, C_{ar3}); 82.0 (d, $J_{C,F}^1 = 137.0$ Hz, CH_2CH_2F); 58.0 (d, $J_{C,F} = 11.9$ Hz), 57.8 (d, $J_{C,F} = 16.4$ Hz), (CH_2CH_2F); 55.1 (s, $C_{pip2,6}$); 50.3 (s, $C_{pip3,5}$); 46.0 (s, CH_3). δ_F (282 MHz, 298 K, d_6 -DMSO) [ppm] = -119.2 (d, $J_{F,F}^4 = 11.0$ Hz, 3 F, $C_{ar6}F$); -127.6 (q, $J_{F,F} = 5.6$ Hz, 3 F, $C_{ar8}F$); -224.2 (d, $J_{C,F}^6 = 6.0$ Hz, 3 F, $(CH_2)_2F$). **MS** (ES+, CH_3OH): m/z (%) = 1197 (80) [$ML_3 + Na^+$], 806 (100) [ML_2]⁺. **HR-ESI-MS:** m/z for $C_{51}H_{51}F_9$ $^{69}GaN_9O_9 + Na^+$ calcd. (found): 1196.2820 (1196.2838); for $C_{34}H_{34}F_6$ $^{69}GaN_6O_6^+$ calcd. (found): 805.1700 (805.1719).

S2.4 Tris(levofloxacinogallium(III), [Ga(levox)₃]

Method (a) gave a yellow solid (47 mg, 0.041 mmol, 41%). **Mp:** $\geq 190^\circ C$, decomposition to orange-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3426 (md, br, water), 3033 (w, br), 2931 (w), 2848 (w), 2794 (w), 1616 (st), 1519 (st), 1447 (st), 1385 (md, sh), 1331 (st, br), 1261 (st), 1150 (sh), 1129 (md), 1093 (md), 1047 (st), 1003 (md), 978 (st), 898 (md), 866 (md),

844 (w), 810 (st), 763 (md), 744 (st), 696 (md), 638 (w), 554 (md), 510 (st), 463 (md, br). **NMR:** δ_H (600 MHz, 298 K, d_6 -DMSO) [ppm] = 9.25 (s), 9.19 (s), 9.13 (s), 9.01 (s), 9.98 (s), 9.93 (s), 8.98 (s), (3 H, $C_{ar2}H$); 7.60 (d, $J_{H,F}^3 = 12.0$ Hz), 7.48–7.45 (m), 7.42 (d, $J_{H,F}^3 = 12.0$ Hz), 7.29 (d, $J_{H,F}^3 = 12.0$ Hz), 7.24–7.211, 7.14 (d, $J_{H,F}^3 = 12.6$ Hz), (3 H, $C_{ar5}H$); 5.08–4.88 (m, 3 H, CH); 4.64–4.27 (m, 6 H, OCH_2CH); 3.50–3.26 (m, 12 H overlaid with water, $C_{pip2,6}H_2$); 2.76–2.61 (m, 12 H, $C_{pip3,5}H_2$); 2.46–2.38 (m, 9 H, NCH_3); 1.52–1.42 (m), 1.23 (br s), 1.14–1.08 (m), (9 H, $CHCH_3$). δ_C (125 MHz, 298 K, d_6 -DMSO) [ppm] = 176.4 (s), 173.6 (s), 173.4 (s), 173.2 (s), (C_{ar4}); 166.0 (s), 165.8 (s), 165.6 (s), 165.4 (s), ($COOH$); 155.5 (d, $J_{C,F}^1 = 204.8$ Hz), 155.4 (d, $J_{C,F}^1 = 203.3$ Hz), 155.2 (d, $J_{C,F}^1 = 200.0$ Hz), (C_{ar6}); 148.2 (s), 147.9 (s), 147.7 (s), 147.5 (s), 146.3 (s), (C_{ar2}); 140.4 (d, $J_{C,F}^3 = 5.8$ Hz), 139.8 (d, $J_{C,F}^3 = 8.9$ Hz), 139.2 (d, $J_{C,F}^3 = 10.4$ Hz), (C_{ar8}); 131.1–130.8 (m, C_{ar7}); 124.9 (s), 124.6 (s), 124.5 (s), 124.2 (s), ($C_{ar8'}$); 120.0 (s), 119.8 (s), 119.5 (s), 119.4 (s) ($C_{ar4'}$); 112.6 (s), 112.5 (s), 111.8 (s), 111.6 (s), 106.7 (s), (C_{ar3}); 103.3 (d, $J_{C,F}^2 = 20.4$ Hz), 102.9 (d, $J_{C,F}^2 = 24.5$ Hz), 102.3 (d, $J_{C,F}^2 = 22.8$ Hz), (C_{ar5}); 68.2 (s), 68.0 (s), 67.9 (s), (OCH_2CH); 55.2 (s), 55.0 (s), 54.8 (s), ($C_{pip2,6}$); 54.7 (s), 54.6 (s), 54.5 (s), (CH); 49.4–48.8 (m, $C_{pip3,5}$); 45.2–44.4 (m, NCH_3); 18.2–17.7 (m, $CH(CH_3)$). δ_F (282 MHz, 298 K, d_6 -DMSO) [ppm] = -119.4 (s), -119.5 (s), -119.7 (s), -119.8 (s), -119.86 (s), -119.93 (s), (3 F, $C_{ar6}F$). **MS** (ES+, CH_3OH): m/z (%) = 1173 (40) [$ML_3 + Na^+$], 790 (100) [ML_2]⁺. **HR-ESI-MS:** m/z for $C_{54}H_{57}F_3$ $^{69}GaN_9O_{12} + Na^+$ calcd. (found): 1172.3232 (1172.3248); for $C_{36}H_{38}F_2$ $^{69}GaN_6O_8^+$ calcd. (found): 789.1975 (789.1989).

S2.5 Tris(lomefloxacin)gallium(III), [$Ga(lomx)_3$]

Method (a) gave a pale yellow solid (40 mg, 0.035 mmol, 35%). **Mp:** $\geq 200^\circ C$, decomposition to brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3419 (md, br, water), 2980 (w, br), 2848

(w, br), 2478 (w, br), 1619 (st), 1556 (w), 1523 (st), 1452 (st), 1354 (md, sh), 1323 (st, br), 1277 (md), 1247 (st), 1123 (md), 1090 (md), 1050 (st), 1001 (st), 932 (st), 886 (md), 811 (st), 776 (w), 742 (md), 651 (md), 542 (sh), 505 (md, br). **NMR:** $\delta_{\mathbf{H}}$ (600 MHz, 298 K, D₂O) [ppm] = 9.18 (s), 9.15 (s), 9.01 (s), 9.05 (s), 8.94 (s), (3 H, $C_{ar2}H$); 7.87 (d, $J_{H,F}^3 = 11.4$ Hz), 7.66 (d, $J_{H,F}^3 = 11.4$ Hz), 7.61 (d, $J_{H,F}^3 = 10.8$ Hz), 7.51 (d, $J_{H,F}^3 = 10.2$ Hz), (3 H, $C_{ar5}H$); 4.68–4.58 (m, 6 H, CH_2CH_3); 3.43–3.28 (m, 12 H, $C_{pip2,6}H_2$, and 3 H, $C_{pip3}H$); 3.10–2.91 (m, 12 H, $C_{pip4}H_2$); 1.48–1.34 (m, 9 H, CH_2CH_3); 1.10–1.07 (m, 9 H, CH_3). $\delta_{\mathbf{C}}$ (125 MHz, 298 K, d_6 -DMSO) [ppm] = 175.7 (s), 173.1 (s), 172.8 (s), (C_{ar4}); 165.7 (s), 165.3 (s), 165.0 (s), 164.1 (s), ($COOH$); 154.8 (d, $J_{C,F}^1 = 207.1$ Hz), 154.6 (d, $J_{C,F}^1 = 205.8$ Hz), 154.6 (d, $J_{C,F}^1 = 207.8$ Hz), (C_{ar6}); 153.4 (s), 153.1 (s), 152.8 (s), 151.4 (s), (C_{ar2}); 146.2 (d, $J_{C,F}^1 = 207.0$ Hz); 146.1 (d, $J_{C,F}^1 = 207.4$ Hz); 145.5 (d, $J_{C,F}^1 = 212.2$ Hz), (C_{ar8}); 133.7 (s), 133.6 (s), 133.5 (s), 133.4 (s), (C_{ar7}); 127.4 (d, $J_{C,F}^2 = 5.5$ Hz), 127.2 (d, $J_{C,F}^2 = 5.0$ Hz), ($C_{ar8'}$); 120.8 (d, $J_{C,F}^3 = 6.3$ Hz), 120.4 (d, $J_{C,F}^3 = 6.0$ Hz), ($C_{ar4'}$); 112.3 (s), 112.2 (s), 112.1 (s), (C_{ar5}); 107.2 (s), 107.1 (s), 106.6 (s), (C_{ar3}); 56.5 (s), 56.4 (s), 56.3 (s), (C_{pip2}); 54.2 (s), 54.1 (s), 53.9 (s), 53.8 (s), (CH_2CH_3); 51.0 (s), 50.9 (s), 49.5 (s), (C_{pip6}); 49.5 (br s, C_{pip3}); 44.9 (br, s, C_{pip5}); 17.9 (s), 17.7 (br s) (CH_2CH_3); 16.3 (s), 16.2 (s), 16.1 (s), (CH_3). $\delta_{\mathbf{F}}$ (282 MHz, 298 K, d_6 -DMSO) [ppm] = (-118.8)–(-118.9) (m), -119.4 (d, $J_{F,F}^4 = 10.7$ Hz), (3 F, $C_{ar6}F$); -129.4 (d, $J_{F,F}^4 = 10.4$ Hz), (-129.9)–(-130.4) (m), (3 F, $C_{ar8}F$). **MS** (ES+, CH_3OH): m/z (%) = 1143 (30) [$ML_3 + Na^+$], 770 (100) [ML_2]⁺. **HR-ESI-MS:** m/z for $C_{51}H_{54}F_6$ $^{69}GaN_9O_9 + Na^+$ calcd. (found): 1142.3102 (1142.3093).

S2.6 Tris(nalidixo)gallium(III), [Ga(nxa)₃]

Method (b) gave an off-white solid (37 mg, 0.046 mmol, 46%). **Mp**: $\geq 190^\circ\text{C}$, decomposition to beige-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3443 (md, br, water), 3025 (md, br), 2985 (w), 1676 (sh), 1608 (st, br), 1557 (st), 1518 (sh), 1490 (st), 1440 (st), 1380 (w), 1365 (md), 1348 (md), 1320 (md), 1293 (st), 1256 (st), 1227 (sh), 1168 (w), 1130 (st), 1109 (w), 1089 (md), 991 (w, br), 944 (w), 898 (md), 843 (w), 807 (st), 776 (st), 702 (w), 663 (md), 639 (md), 561 (sh), 543 (md), 506 (st), 452 (st). **NMR**: δ_{H} (600 MHz, 298 K, d_6 -DMSO) [ppm] = 9.45 (s), 9.35 (s), 9.27 (s), 9.19 (s), (3 H, $C_{ar2}H$); 8.62 (d, $J_{H,H}^3 = 8.2$ Hz), 8.43–8.31 (m) (3 H, $C_{ar5}H$); 7.61 (d, $J_{H,H}^3 = 8.2$ Hz), 7.56 (d, $J_{H,H}^3 = 8.4$ Hz), 7.51 (d, $J_{H,H}^3 = 7.8$ Hz), (3 H, $C_{ar6}H$); 4.76–4.57 (m, 6 H, CH_2CH_3); 2.69 (d, $J_{H,H}^4 = 30.0$ Hz, 9 H, $C_{ar7}CH_3$); 1.45 (t, $J_{H,H}^3 = 6.9$ Hz), 1.42 (t, $J_{H,H}^3 = 7.1$ Hz), 1.31 (t, $J_{H,H}^3 = 7.1$ Hz), (9 H, CH_2CH_3). δ_{C} (125 MHz, 298 K, d_6 -DMSO) [ppm] = 178.1 (s), 175.6 (s), 175.4 (s), 175.2 (s), (C_{ar4}); 165.6 (s), 165.3 (s), 165.1 (s), 165.0 (s), (C_{ar8}); 164.9 (s), 164.8 (s), 164.7 (s), (COOH); 151.7 (s), 151.4 (s), 151.3 (s), 151.1 (s), (C_{ar2}); 149.7 (s), 148.4 (s), 147.7 (s), 147.4 (s), (C_{ar7}); 135.9 (s), 135.7 (s), 135.4 (s), 135.3 (s), (C_{ar5}); 123.0 (s), 122.9 (s), 122.6 (s), (C_{ar6}); 118.4 (s), 118.2 (s), 118.1 (s), 118.0 (s), ($C_{ar4'}$); 113.7 (s), 113.6 (s), 113.3 (s), (C_{ar3}); 47.1 (s), 47.0 (s), 46.9 (s), 46.8 (s), (CH_2CH_3); 25.1 (br s) (CH_3); 15.2 (s), 15.1 (s), 15.0 (s), (CH_2CH_3). **MS** (ES+, CH_3OH): m/z (%) = 1296 (10) [M_2L_5]⁺, 785 (100) [$\text{ML}_3 + \text{Na}^+$], 531 (20) [ML_2]⁺. **HR-ESI-MS**: m/z for $\text{C}_{36}\text{H}_{33}^{69}\text{GaN}_6\text{O}_9 + \text{Na}^+$ calcd. (found): 785.1463 (785.1479). **EA**: Anal. Calcd. (found) [%] for $\text{C}_{36}\text{H}_{33}\text{GaN}_6\text{O}_9 \cdot 1.5 \text{H}_2\text{O}$: C, 54.70 (54.59); H, 4.59 (4.42); N, 10.63 (10.24).

S2.7 Tris(norfloxacinogallium(III), [Ga(nofx)₃]

Method (a) gave a pale yellow solid (38 mg, 0.036 mmol, 36%). **Mp:** $\geq 200^{\circ}\text{C}$, decomposition to orange-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3391 (md, br, water), 2839 (w, br), 1615 (st, br), 1551 (w), 1519 (md), 1471 (st, br), 1377 (md), 1320 (md), 1255 (st, br), 1188 (md), 1129 (md), 1089 (w), 1037 (md), 971 (w), 930 (st), 889 (sh), 812 (st), 788 (md), 769 (md), 747 (st), 697 (w), 628 (st), 561 (md), 513 (st). **NMR:** δ_{H} (600 MHz, 298 K, d_6 -DMSO) [ppm] = 9.19 (s), 9.09 (s), 9.05 (s), 8.97 (s), (3 H, $C_{ar2}H$); 7.94 (d, $J_{H,F}^3 = 13.2$ Hz), 7.75 (d, $J_{H,F}^3 = 13.2$ Hz), 7.57 (d, $J_{H,F}^3 = 13.8$ Hz), 7.53 (d, $J_{H,F}^3 = 13.2$ Hz), (3 H, $C_{ar5}H$); 7.26 (d, $J_{H,F}^4 = 6.6$ Hz), 7.21 (d, $J_{H,F}^4 = 7.8$ Hz), 7.19 (d, $J_{H,F}^4 = 7.2$ Hz), 7.13 (d, $J_{H,F}^4 = 7.2$ Hz), (3 H, $C_{ar8}H$); 4.70–4.48 (m, 6 H, CH_2CH_3); 3.44–3.31 (m, 12 H overlaid with water, $C_{pip2,6}H_2$); 3.09–3.02 (m, 12 H, $C_{pip3,5}H_2$); 1.46–1.40 (m), 1.30 (t, $J_{H,H}^3 = 7.2$ Hz), (9 H, CH_2CH_3). δ_{C} (125 MHz, 298 K, d_6 -DMSO) [ppm] = 173.5 (s), 172.9 (s), 172.8 (s), (C_{ar4}); 165.7 (s), 165.6 (s), 165.4 (s), (COOH); 152.9 (d, $J_{C,F}^1 = 208.4$ Hz), 152.7 (d, $J_{C,F}^1 = 206.9$ Hz), (C_{ar6}); 150.5 (s), 150.0 (s), 149.9 (s), (C_{ar2}); 145.5–145.0 (m, C_{ar7}); 136.9, 136.8, 136.6 ($C_{ar8'}$); 119.3 (d, $J_{C,F}^3 = 7.8$ Hz), 119.2 (d, $J_{C,F}^3 = 8.2$ Hz), 119.0 (d, $J_{C,F}^3 = 7.4$ Hz), ($C_{ar4'}$); 112.0–110.4 (m, C_{ar5} and C_{ar3}); 105.5 (s), 105.3 (s), 105.0 (s), (C_{ar8}); 49.4–48.5 (m, $C_{pip2,6}$ and CH_2CH_3); 44.4 (s), 44.2 (s), 44.1 (s), 44.0 (s), ($C_{pip3,5}$); 14.62 (s), 14.60 (s), 14.5 (s), 14.4 (s), (CH_2CH_3). δ_{F} (282 MHz, 298 K, d_6 -DMSO) [ppm] = -120.9 (s), -121.0 (s), -121.1 (s), -121.2 (s), (3 F, $C_{ar6}F$). **MS** (ES+, CH_3OH): m/z (%) = 1047 (10) [$\text{ML}_3 + \text{Na}^+$], 706 (100) [ML_2]⁺. **HR-ESI-MS:** m/z for $\text{C}_{48}\text{H}_{51}\text{F}_3$ $^{69}\text{GaN}_9\text{O}_9 + \text{Na}^+$ calcd. (found): 1046.2915 (1046.2925).

S2.8 Tris(oxalino)gallium(III), [Ga(oxa)₃]

Method (b) gave an off-white solid (69 mg, 0.082 mmol, 82%). **Mp**: $\geq 240^\circ\text{C}$, decomposition to beige-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3402 (md, br), 3060 (w, br), 2979 (w, br), 2918 (w,br), 1637 (st), 1599 (st), 1567 (md), 1539 (st), 1463 (st, br), 1412 (sh), 1387 (md), 1329 (md), 1258 (st, br), 1193 (md), 1158 (w), 1126 (w), 1087 (w), 1029 (st, br), 933 (md), 904 (md), 846 (w), 812 (st), 777 (st, br), 656 (md), 618 (md), 563 (w). **NMR**: δ_{H} (600 MHz, 298 K, *d*₆-DMSO) [ppm] = 8.90 (s, 3 H, *C*_{ar2}*H*); 7.64 (s, 3 H, *C*_{ar8}*H*); 7.63 (s, 3 H, *C*_{ar5}*H*); 6.30 (s, 6 H, OCH₂O); 4.53 (q, $J_{\text{H,H}}^3 = 7.1$ Hz, 6 H, CH₂CH₃); 1.37 (t, $J_{\text{H,H}}^3 = 7.1$ Hz, 9 H, CH₂CH₃). δ_{C} (125 MHz, 298 K, *d*₆-DMSO) [ppm] = 176.0 (s, *C*_{ar4}); 166.3 (s, COOH); 153.7 (s, *C*_{ar7}); 147.1 (s, *C*_{ar6}); 147.0 (s, *C*_{ar2}); 136.9 (s, *C*_{ar8'}); 121.3 (s, *C*_{ar4'}); 107.4 (s, *C*_{ar3}); 103.3 (s, OCH₂O); 101.9 (s, *C*_{ar5}); 97.3 (s, *C*_{ar8}); 49.6 (s, CH₂CH₃); 14.6 (s, CH₂CH₃). **MS** (ES+, CH₃OH): *m/z* (%) = 873 (100) [ML₃ + Na⁺], 589 (80) [ML₂]⁺. **HR-ESI-MS**: *m/z* for C₃₉H₃₀⁶⁹GaN₃O₁₅ + Na⁺ calcd. (found): 872.0830 (872.0822). **EA**: Anal. Calcd. (found) [%] for C₃₉H₃₀GaN₃O₁₅·3.5 H₂O: C, 51.28 (51.37); H, 4.08 (3.97); N, 4.60 (4.70).

S2.9 Tris(pipemido)gallium(III), [Ga(pia)₃]

Method (b) gave an off-white solid (64 mg, 0.066 mmol, 66%). **Mp**: $\geq 190^\circ\text{C}$, decomposition to beige-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3373 (st, br, water), 3029 (w), 2980 (w), 1616 (st), 1578 (st), 1536 (md), 1510 (md), 1471 (st), 1430 (st), 1378 (sh), 1358 (st, br), 1310 (md), 1280 (md), 1249 (st, br), 1159 (w), 1148 (w), 1128 (st), 1092 (md), 1079 (md), 1045 (md), 1024 (st), 976 (md), 940 (md), 915 (st), 903 (md) 868 (md), 832 (st), 802 (md), 744 (st), 715 (md), 703 (md), 657 (w), 609 (w), 541 (md), 489 (md), 463 (st). **NMR**: δ_{H} (600 MHz, 298 K, *d*₆-DMSO) [ppm] = 9.17 (s, 3 H, *C*_{ar5}*H*); 8.94 (s, 3 H, *C*_{ar2}*H*); 4.37 (q,

$J_{H,H}^3 = 7.1$ Hz, 6 H, CH_2CH_3); 3.85 (d, $J_{H,H} = 40.1$ Hz, 12 H, $C_{\text{pip}2,6H_2}$); 2.78 (d, $J_{H,H} = 16.2$ Hz, 12 H, $C_{\text{pip}3,5H_2}$); 1.35 (t, $J_{H,H}^3 = 6.9$ Hz, 9 H, CH_2CH_3). δ_C (125 MHz, 298 K, d_6 -DMSO) [ppm] = 177.1 (s, C_{ar4}); 165.4 (s, COOH); 160.6 (s, C_{ar7}); 160.1 (s, C_{ar5}); 155.1 (s, $C_{ar8'}$); 150.6 (s, C_{ar2}); 109.7 (s, $C_{ar4'}$); 108.3 (s, C_{ar3}); 45.9 (s, CH_2CH_3); 45.6 (s), 45.3 (s), ($C_{\text{pip}2,3,5,6}$); 14.4 (s, CH_2CH_3). **MS** (ES+, CH_3OH): m/z (%) = 999 (100) $[\text{ML}_3 + \text{Na}^+]$, 673 (80) $[\text{ML}_2]^+$. **HR-ESI-MS**: m/z for $\text{C}_{42}\text{H}_{48}^{69}\text{GaN}_{15}\text{O}_9 + \text{Na}^+$ calcd. (found): 998.2913 (998.2939); for $\text{C}_{28}\text{H}_{32}^{69}\text{GaN}_{10}\text{O}_6^+$ calcd. (found): 673.1762 (673.1776). **EA**: Anal. Calcd. (found) [%] for $\text{C}_{42}\text{H}_{48}\text{GaN}_{15}\text{O}_9 \cdot 12.5 \text{H}_2\text{O}$: C, 41.97 (41.70); H, 6.12 (5.85); N, 17.48 (17.26).

S2.10 Tris(ciprofloxacin)iron(III), $[\text{Fe}(\text{cipro})_3]$

Method (c) gave a red-brown solid (51 mg, 0.049 mmol, 49%). **Mp**: $\geq 220^\circ\text{C}$, decomposition to black-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3411 (w, br, water), 2846 (w, br), 1610 (st), 1543 (w), 1513 (sh), 1450 (st, br), 1371 (md, br), 1285 (sh), 1252 (st), 1182 (md), 1129 (md), 1108 (sh), 1026 (st), 949 (st), 890 (md), 809 (md), 788 (md), 761 (sh), 738 (st), 702 (md), 627 (st), 577 (md), 556 (w), 538 (w), 506 (st). **MS** (ES+, CH_3OH): m/z (%) = 1763 (≤ 10) $[\text{M}_2\text{L}_5]^+$, 716 (100) $[\text{ML}_2]^+$. **HR-ESI-MS**: m/z for $\text{C}_{51}\text{H}_{51}\text{F}_3^{56}\text{FeN}_9\text{O}_9 + \text{Na}^+$ calcd. (found): 1069.3009 (1069.3007). **EA**: Anal. Calcd. (found) [%] for $\text{C}_{51}\text{H}_{51}\text{F}_3\text{FeN}_9\text{O}_9 \cdot 2.5 \text{H}_2\text{O}$: C, 56.10 (56.04); H, 5.17 (4.80); N, 11.55 (11.27).

S2.11 Tris(enoxacin)iron(III), $[\text{Fe}(\text{enox})_3]$

Method (b) gave a red-orange solid (59 mg, 0.058 mmol, 58%) **Mp**: $\geq 200^\circ\text{C}$, decomposition to black brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3403 (md, br, water), 3039 (w, br), 2976 (w, br), 1626 (st), 1565 (md), 1516 (md), 1441 (st, br), 1368 (md), 1347 (md), 1323 (md), 1275

(st), 1251 (st, br), 1184 (md), 1153 (w), 1119 (md), 1093 (md), 1039 (md, br), 971 (md), 943 (md, br), 907 (sh), 812 (st), 788 (md), 763 (md), 744 (md), 677 (w), 650 (md), 625 (st), 562 (md), 518 (st). **MS** (ES+, CH₃NO₂): m/z (%) = 694 (100) [ML₂]⁺ **HR-ESI-MS**: m/z for C₄₅H₄₈F₃⁵⁶FeN₁₂O₉ + Na⁺ calcd. (found): 1036.2866 (1036.2866). **EA**: Anal. Calcd. (found) [%] for C₄₅H₄₈F₃FeN₁₂O₉·3 H₂O: C, 50.62 (50.48); H, 5.10 (4.82); N, 15.74 (16.07).

S2.12 Tris(fleroxacino)iron(III), [Fe(flex)₃]

Method (b) gave a red-brown solid (91 mg, 0.078 mmol, 78%). **Mp**: ≥230°C, decomposition to brown solid. **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3054 (w), 2930 (md), 2848 (md), 2792 (md), 1625 (st), 1548 (w), 1526 (md), 1471 (sh), 1447 (st, br), 1413 (md), 1389 (w), 1377 (md), 1358 (md), 1325 (md), 1295 (st), 1245 (md), 1236 (sh), 1203 (md), 1160 (md), 1144 (st), 1121 (md), 1097 (w), 1075 (w), 1045 (md), 1026 (st), 1002 (st), 963 (md), 949 (md, br), 896 (md), 861 (md), 803 (st), 779 (md), 752 (md), 736 (md), 714 (md), 648 (st), 599 (md), 568 (st), 536 (w, br), 517 (w), 491 (w), 474 (w). **MS** (ES+, CH₃OH): m/z (%) = 1184 (20) [ML₃ + Na⁺], 793 (100) [ML₂]⁺. **HR-ESI-MS**: m/z for C₅₁H₅₁F₉⁵⁶FeN₉O₉ + Na⁺ calcd. (found): 1183.2913 (1183.2938); for C₃₄H₃₄F₆⁵⁶FeN₆O₆⁺: 792.1793 (792.1785). **EA**: Anal. Calcd. (found) [%] for C₅₁H₅₁F₉FeN₉O₉: C, 52.77 (52.78); H, 4.43 (4.53); N, 10.86 (10.49).

S2.13 Tris(levofloxacino)iron(III), [Fe(levox)₃]

Method (a) gave a red-brown solid (102 mg, 0.090 mmol, 90%). **Mp**: ≥190°C, decomposition to black-brown solid. **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3427 (water), 3041 (w, br), 2935 (w), 2846 (w), 2797 (w), 1615 (st), 1518 (st), 1443 (st), 1382 (md, br), 1330 (st, br), 1291 (w),

1256 (st, br), 1150 (sh), 1129 (md), 1094 (md), 1048 (st), 1003 (md), 978 (st), 896 (md), 864 (w), 843 (w), 826 (sh), 810 (st), 759 (md), 742 (md), 693 (md), 637 (w), 553 (md, br), 508 (st), 443 (st, br). **MS** (ES+, CH₃OH): m/z (%) = 1160 (40) [ML₃ + Na⁺], 777 (100) [ML₂]⁺. **HR-ESI-MS**: m/z for C₅₄H₅₇F₃ ⁵⁶FeN₉O₁₂ + Na⁺ calcd. (found): 1159.3326 (1159.3328); for C₃₆H₃₈F₂ ⁵⁶FeN₆O₈ calcd. (found): 776.2069 (776.2065).

S2.14 Tris(lomefloxacin)iron(III), [Fe(lomx)₃]

Method (b) gave a red-brown solid (80 mg, 0.072 mmol, 72%). **Mp**: $\geq 210^\circ\text{C}$, decomposition to black-brown solid. **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3423 (w, br), 2979 (w, br), 2844 (w, br), 2725 (w, br), 2467 (w, br), 1616 (st), 1552 (w), 1520 (st), 1446 (st), 1358 (md, sh), 1321 (st, br), 1275 (w), 1244 (st), 1122 (md), 1089 (md), 1049 (st), 1002 (st), 932 (st), 880 (md), 810 (st), 760 (md, br), 738 (md), 654 (md), 541 (sh), 502 (md), 449 (md). **MS** (ES+, CH₃OH): m/z (%) = 1130 (10) [ML₃ + Na⁺], 756 (100) [ML₂]⁺. **HR-ESI-MS**: m/z for C₅₁H₅₄F₆ ⁵⁶FeN₉O₉ + Na⁺ calcd. (found): 1129.3196 (1129.3193).

S2.15 Tris(nalidixic acid)iron(III), [Fe(nxa)₃]

Method (b) gave a red-brown solid (66 mg, 0.089 mmol, 89%). **Mp**: $\geq 180^\circ\text{C}$, decomposition to black-brown solid. **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3436 (water), 3023 (md, br), 2983 (w), 1668 (sh), 1606 (st, br), 1556 (st), 1515 (sh), 1486 (st), 1440 (st), 1366 (md), 1347 (md), 1313 (md), 1289 (st), 1255 (st), 1226 (sh), 1168 (w), 1129 (st), 1089 (md), 990 (w, br), 942 (w), 895 (md), 842 (w), 806 (st), 769 (st), 702 (w), 663 (md), 639 (md), 559 (w), 545 (md), 503 (st), 442 (st). **MS** (ES+, CH₃OH): m/z (%) = 1268 (≤ 10) [M₂L₅]⁺, 772 (100) [ML₃ + Na⁺], 518 (40) [ML₂]⁺. **HR-ESI-MS**: m/z for C₃₆H₃₃ ⁵⁶FeN₆O₉ + Na⁺ calcd. (found): 772.1556 (772.1562). **EA**: Anal. Calcd. (found) [%] for C₃₆H₃₃FeN₆O₉·1 H₂O:

C, 56.33 (56.62); 4.60 (4.80); N, 10.95 (11.05).

S2.16 Tris(norfloraxino)iron(III), [Fe(nofx)₃]

Method (b) gave a red-brown solid (68 mg, 0.067 mmol, 67%). **Mp**: $\geq 190^\circ\text{C}$, decomposition to black-brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3371 (md, br, water), 2838 (w, br), 1610 (st, br), 1547 (w), 1516 (md), 1453 (st, br), 1380 (st), 1324 (md), 1282 (sh), 1252 (st, br), 1186 (st), 1124 (md, br), 1024 (md), 923 (st, br), 891 (sh), 875 (w), 810 (md), 786 (md), 760 (md), 738 (st), 694 (w), 624 (md), 558 (md), 512 (md), 443 (md, br). **MS** (ES+, CH₃OH): m/z (%) = 692 (100) [ML₂]⁺, 1033 (20) [ML₃ + Na⁺]. **HR-ESI-MS**: m/z for C₄₈H₅₁F₃ ⁵⁶FeN₉O₉ + Na⁺ calcd. (found): 1033.3009 (1033.3002). **EA**: Anal. Calcd. (found) [%] for C₄₈H₅₁F₃FeN₉O₉·6 H₂O: C, 51.52 (51.42); H, 5.67 (5.72); N, 11.27 (10.89).

S2.17 Tris(oxalino)iron(III), [Fe(oxa)₃]

Method (b) gave a golden-brown solid (70 mg, 0.084 mmol, 84%). **Mp**: $\geq 240^\circ\text{C}$, decomposition to brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3030 (w, br), 2979 (w, br), 2913 (w, br), 1633 (st), 1604 (st), 1563 (md), 1536 (md), 1493 (sh), 1460 (st, br), 1410 (sh), 1385 (md), 1319 (md), 1288 (md), 1259 (st, br), 1198 (st), 1155 (w), 1130 (w), 1079 (w), 1041 (st, br), 978 (w), 934 (md), 899 (w), 886 (w), 875 (w), 849 (w), 813 (st), 775 (st), 759 (sh), 714 (w), 656 (md), 621 (md), 570 (md), 524 (st), 504 (sh), 455 (st). **MS** (ES+, CH₃OH): m/z (%) = 860 (≤ 10) [ML₃ + Na⁺], 576 (100) [ML₂]⁺. **HR-ESI-MS**: m/z for C₃₉H₃₀ ⁵⁶FeN₃O₁₅ + Na⁺ calcd. (found): 859.0924 (859.0914). **EA**: Anal. Calcd. (found) [%] for C₃₉H₃₀FeN₃O₁₅·1.5 H₂O: C, 54.24 (54.24); H, 3.85 (3.72); N, 4.87 (4.74).

S2.18 Tris(pipemido)iron(III), [Fe(pia)₃]

Method (b) gave a brown solid (78 mg, 0.081 mmol, 81%). **Mp**: $\geq 200^\circ\text{C}$, decomposition to brown solid. **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3406 (md, br), 3028 (w), 2979 (w), 1615 (st), 1578 (st) 1534 (md), 1510 (md), 1471 (st), 1429 (st), 1377 (sh), 1357 (st, br), 1310 (md), 1280 (md), 1248 (st, br), 1158 (w), 1147 (w), 1128 (st), 1092 (md), 1078 (md), 1045 (md), 1023 (st), 975 (md), 940 (md), 914 (st), 903 (md), 867 (w), 832 (st), 802 (md), 784 (md), 744 (st), 715 (md), 704 (sh), 656 (w), 609 (w), 540 (md), 489 (md), 454 (st). **MS** (ES+, CH₃OH): m/z (%) = 986 (20) [ML₃ + Na⁺], 715 (100) [ML₂·3H₂O]⁺, 661 [ML₂]⁺ (10). **HR-ESI-MS**: m/z for C₄₂H₄₈⁵⁶FeN₁₅O₉ (M + Na⁺) calcd. (found): 985.3007 (985.3017). **EA**: Anal. Calcd. (found) [%] for C₄₂H₄₈FeN₁₅O₉·4 H₂O: C, 48.75 (48.94); H, 5.45 (6.23); N, 20.30 (20.33).

S3 Synthesis & Characterization of Tris(maltolato)metal(III) Complexes**S3.1 Tris(maltolato)gallium(III), [Ga(ma)₃]**

The synthesis followed the literature procedure.⁴ Scale: 3-hydroxy-2-methyl-4*H*-pyran-4-one (2.60 g, 20.55 mmol), gallium(III) nitrate nonahydrate (2.86 g, 6.85 mmol), water (40 mL). Yield: off-white solid (1.957 g, 4.40 mmol, 64%). **IR** (neat): $\tilde{\nu}$ [cm^{-1}] = 3027 (w), 1611 (sh), 1568 (st), 1514 (st), 1456 (st), 1295 (sh), 1277 (st), 1241 (md), 1192 (st), 1087 (w), 1043 (md), 921 (md), 850 (st), 830 (st), 745 (st), 720 (st), 664 (md), 617 (md), 557 (sh), 528 (sh), 511 (w), 493 (md). **MS** (ES+, CH₃OH): m/z (%) = 765 (100) [M₂L₅]⁺, 445 (10) [ML₃H⁺], 319 (40) [ML₂]⁺. **HR-ESI-MS**: m/z for C₁₈H₁₅⁶⁹GaO₉ (M + Na⁺) calcd. (found): 466.9870 (466.9866). **EA**: Anal. Calcd. (found) [%] for C₁₈H₁₅GaO₉·1 H₂O: C,

46.69 (46.77); H, 3.70 (3.34).

S3.2 Tris(maltolato)iron(III), [Fe(ma)₃]

The synthesis followed the literature procedure.⁵ Scale: 3-hydroxy-2-methyl-4*H*-pyran-4-one (3.792 g, 3.0 mmol), iron(III) nonahydrate (4.037 g, 1.0 mmol), water and ethanol (100 mL each). Yield: ruby-red solid (0.354 g, 0.82 mmol, 82%). **IR** (neat): $\tilde{\nu}$ [cm⁻¹] = 3024 (w), 1605 (sh), 1564 (st), 1505 (st), 1455 (st), 1293 (sh), 1272 (st), 1238 (md), 1190 (st), 1084 (w), 1038 (md), 920 (md), 849 (st), 829 (st), 745 (st), 719 (st), 664 (md), 607 (md), 536 (st), 470 (st). **MS** (ES+, CH₃OH): m/z (%) = 737 (20) [M₂L₅]⁺, 454 (70) [ML₃Na⁺], 306 (100) [ML₂]⁺. **HR-ESI-MS**: m/z for C₁₈H₁₅⁵⁶FeO₉ (M + Na⁺) calcd. (found): 453.9963 (453.9963). **EA**: Anal. Calcd. (found) [%] for C₁₈H₁₅FeO₉·2 H₂O: C, 46.28 (46.19); H, 4.10 (3.86).

S4 Antimicrobial Susceptibility Single-Disk Test Procedure

This procedure describes the antimicrobial susceptibility testing by single-disk method following a modified version of the original procedure by Kirby and Bauer⁶⁷ taking into account recommendations from the CLSI⁸⁹ and EUCAST¹⁰ test procedures. One major deviation from the CLSI and EUCAST test procedures is the use of Iso-Sensitest medium instead of Mueller-Hinton medium. It should be clarified that both biological growth media, Iso-Sensitest¹¹ and Mueller-Hinton,¹² contain relatively large amounts of metal salts compared to the concentrations of test compounds (0.1 mM), after all these are nutrient rich media to grow biological cultures. The fact, however, that Mueller-Hinton medium is less defined than the purely synthetic Iso-Sensitest medium and that the composition of Mueller-Hinton, especially in regard to cations, such as Ca²⁺ and Mg²⁺, has been

known to vary widely across manufacturers and even across different batches from the same manufacturer,¹³ made Iso-Sensitest medium occur as the better choice of the necessary evil, as at least the ingredients of Iso-Sensitest medium are clearly defined. Furthermore, test results of several potential metalloantimicrobials in Iso-Sensitest medium have been reported in the literature without any comments regarding cross-metalation, including coordination complexes of gallium(III)^{14,15} and iron(III).¹⁶

The antimicrobial tests were performed in UBC's Biological Services Laboratory, a class II facility, following respective operating and safety procedures. Disposable petri dishes (150 mm diameter) were marked with placement positions for not more than fourteen disks per plate and with a distance between each disk (center to center) of at least 24 mm.

The dehydrated Iso-Sensitest media (agar, broth) were prepared according to the manufacturer's specifications; the agar was poured evenly into the dishes to a depth of about 4 mm on a level surface. Bacteria were grown in Iso-Sensitest broth 37 °C on a shaker to an $OD_{600} \geq 1$.

All compound test solutions were prepared fresh on the day of the experiment in methanol and DMSO. The latter was needed to dissolve the test compounds. DMSO was filtered (Millex-FG 0.20 μm) before use, and its concentration was kept below 2% in the test solution. Solutions of pure methanol, 2%-DMSO-methanol, gallium(III) nitrate and iron(III) nitrate were included on each test plate as controls.

The following steps were done in triplicate. The paper filter disks were loaded with 20 μL of the respective test or control solution and left for the solvent to evaporate (about 5 min). During this drying time, the agar plates were inoculated with the respective bacteria growth solution (inoculation volume 0.5 mL). Then, the loaded filter disks were placed on the agar plate in the previously marked positions and carefully pressed onto the agar. The

lid of the test dish was put back. Tightly sealed with parafilm, the test plates were placed upside-down in an incubator at 37 °C for 20 h. On the following day, the test plates were removed from the incubator and inspected for bacterial growth. To do so, each test plate was placed on a non-reflecting black surface so that the zone of no growth around each disk could be determined with the naked eye and measured with a ruler. Following the convention, inhibition zone sizes were recorded as diameters rounded to the nearest millimeter, wherein the diameter of each paper filter disk (0.6 mm) was included in the measurement. If growth was observed up to the edge of a disk, this was recorded as 0 mm inhibition. Taking into account the measured inhibition zone sizes from all three test plates, the average inhibition zone size, including the standard deviation, was calculated for each test compound against each bacterium tested.

S5 MIC and IC₅₀ Studies

Minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC₅₀) studies were performed against *P. aeruginosa* strain K767 PAO1 wild type in cation-adjusted Mueller-Hinton broth at the Centre for Drug Research and Development (CDRD).¹⁷ One colony of the bacterium was picked up and inoculated into 5 mL Mueller-Hinton broth at 37°C overnight. On the next day, the growth solution was diluted to an OD₆₂₅ of 0.112 as the equivalent of 0.5 McFarland standard or $\sim 1\text{-}2 \times 10^8$ CFU/mL; a volume of 0.5 mL of the dilution was further diluted with cation-adjusted Mueller-Hinton broth to a total volume of 50 mL.

On the test day, an acidic (HCl_{aq}) stock solution of ciprofloxacin (0.1 mM) was prepared in deionized water, which had been purified through a ELGA MAXIMA ultra pure water system with a resistivity of 18 MΩ·cm at 25°C, together with aqueous stock solutions

of gallium(III) nitrate nonahydrate (10 mM) and citric acid (10 mM). From these stock solutions, test solutions were prepared at stoichiometric ratios of Ga:Hcipro of 0:1, 1:1, 1:2, 1:3, and 1:4.

A 96-well plate was prepared to test the antimicrobial efficacy of the Ga:Hcipro test solutions against *P. aeruginosa* including as a negative control test solutions without the bacterium and as a positive growth control *P. aeruginosa* only. Using a multichannel pipettor, the test solutions were diluted across the 96-well test plate with Mueller-Hinton broth. A volume of 100 μ L of the diluted *P. aeruginosa* solution was added to the respective wells. Three plates were prepared in parallel, incubated at 37°C overnight, and read for absorbance at OD₆₀₀ the next day. The obtained MIC and IC₅₀ values are summarized in Table S1.

No differences in MIC values were observed for any of the stoichiometric ratios of Ga:Hcipro test solutions in the *P. aeruginosa* growth assay. The obtained MIC value for Table S1: MIC and IC₅₀ values for aqueous solutions of gallium(III) nitrate and ciprofloxacin at different ratios tested against *P. aeruginosa* in Mueller-Hinton broth.

Ratio Ga:Hcipro	pH	MIC [μ g/mL]	IC ₅₀ [μ g/mL]
0:1	2.57	0.129	0.059
1:1	2.43	0.129	0.061
1:2	2.12	0.129	0.038
1:3	1.97	0.194	0.050
1:4	2.97	0.129	0.032
1:0 ^(a)	1.87	–	–

^(a) Aqueous solution of gallium(III) nitrate mixed with an aqueous solution of citrate.

the ciprofloxacin control compared well with the 0.1 mg/L reported for *P. aeruginosa* strain K767 PAO1 wild type by Liz *et al.*¹⁸ Slight, almost insignificant, differences in IC₅₀ values were found for Ga:Hcipro ratios of $\leq 1:2$. In conclusion, no synergistic or combinational effects were observed for the interaction of Ga³⁺ and ciprofloxacin in the solution-based MIC and IC₅₀ studies against *P. aeruginosa*.

References

- [1] A. Zieba, A. Maslankiewicz and J. Sitkowski, *Magn. Reson. Chem.*, 2004, **42**, 903–904.
- [2] N. Barba-Behrens, G. Mendoza-Díaz and D. M. L. Goodgame, *Inorg. Chim. Acta*, 1986, **125**, 21–26.
- [3] G. Psomas, *J. Inorg. Biochem.*, 2008, **102**, 1798–1811.
- [4] M. M. Finnegan, T. G. Lutz, W. O. Nelson, A. Smith and C. Orvig, *Inorg. Chem.*, 1987, **26**, 2171–2176.
- [5] M. T. Ahmet, C. S. Frampton and J. Silver, *J. Chem. Soc., Dalton Trans.*, 1988, 1159–1163.
- [6] A. W. Bauer, D. M. Perry and W. M. M. Kirby, *AMA Arch. Intern. Med.*, 1959, **104**, 208–216.
- [7] A. W. Bauer, W. M. Kirby, J. C. Sherris and M. Turck, *Am. J. Clin. Pathol.*, 1966, **45**, 493–496.
- [8] Clinical Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition*; Standard M02-A11, Vol. 32, No. 1; CLSI: Wayne, PA, USA, 2012.

- [9] Clinical Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement*; Supplement M100-S22, Vol. 32, No. 3; CLSI: Wayne, PA, USA, 2012.
- [10] E. Matuschek, D. F. J. Brown and G. Kahlmeter, *Clin. Microbiol. Infect.*, 2014, **20**, O255–66.
- [11] Oxoid, Iso-Sensitest Broth, Typical Formula of Dehydrated Culture Media; <http://www.oxoid.com> (accessed Mar 01, 2016).
- [12] BBL, *Approximate Formula of Mueller-Hinton II (Cation-Adjusted) Agar*; <http://www.bd.com> (accessed Mar 01, 2016).
- [13] R. F. D’Amato and C. Thornsberry, *Curr. Microbiol.*, 1979, **2**, 135–138.
- [14] O. Rzhepishevskaya, B. Ekstrand-Hammarström, M. Popp, E. Björn, A. Bucht, A. Sjöstedt, H. Antti and M. Ramstedt, *Antimicrob. Agents Chemother.*, 2011, **55**, 5568–5580.
- [15] O. Rzhepishevskaya, S. Hakobyan, B. Ekstrand-Hammarström, Y. Nygren, T. Karlsson, A. Bucht, M. Elofsson, J.-F. Boily and M. J. Ramstedt, *J. Inorg. Biochem.*, 2014, **138**, 1–8.
- [16] I. Turel, I. Leban, G. Klintschar, N. Bukovec and S. Zalar, *J. Inorg. Biochem.*, 1997, **66**, 77–82.
- [17] Centre for Drug Research and Development. *Liposomal Ciprofloxacin-Gallium Coordinated Complexes*; Technical Report No. R0993; CDRD: Vancouver, BC, Canada, 2011.

- [18] X. Liz, N. Barre and K. Poole, *J. Antimicrob. Chemother.*, 2000, **46**, 885–893.